Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Immatics ( (IMTX) ).
On May 31, 2025, Immatics N.V. presented expanded data from its ongoing Phase 1b clinical trial of IMA203 PRAME cell therapy at the ASCO Annual Meeting. The trial involved 33 heavily pretreated patients with metastatic melanoma, demonstrating favorable tolerability and promising clinical activity with durable objective responses lasting over 2.5 years. The confirmed objective response rate was 56%, with a median duration of response of 12.1 months. The data supports the ongoing SUPRAME Phase 3 trial, aimed at evaluating IMA203 in patients with advanced or metastatic cutaneous melanoma, reinforcing Immatics’ leadership in PRAME-targeted therapies.
The most recent analyst rating on (IMTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
Immatics’ stock score is influenced by strong revenue growth but offset by profitability and cash flow challenges. Technical analysis suggests moderate short-term bullish momentum, though longer-term trends remain bearish. Valuation struggles with a negative P/E ratio, common in the biotech industry.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell-redirecting cancer immunotherapies. The company is actively involved in precision targeting of PRAME, a prevalent cancer target expressed in more than 50 types of cancer, and is working towards developing a broad PRAME franchise.
Average Trading Volume: 658,755
Technical Sentiment Signal: Sell
Current Market Cap: $655.2M
For a thorough assessment of IMTX stock, go to TipRanks’ Stock Analysis page.